Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor

Acta Pharmaceutica Sinica B(2022)10.1016/j.apsb.2022.03.023Source: DataRank Database

Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor is a research paper published in Acta Pharmaceutica Sinica B (2022). On theSindex it has a DataRank of 0. It has been cited 35 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access35 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 2.79)OA: goldTopics (26)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Qiu‐Xu Teng,Shuai Wang ORCID,Zi‐Ning Lei ORCID,Huihui Hu ORCID,Huifang Lv ORCID

Live enrichment

PubMed:35967279 PMC:PMC9366537 OpenAlex:https://openalex.org/W4226213049

National Institutes of Health

Grant: 20892

National Natural Science Foundation of China

Grant: 81973177

National Natural Science Foundation of China

Grant: 82103560

National Natural Science Foundation of China

Grant: 82103996

Natural Science Foundation of Henan Province

Grant: 212300410253

Natural Science Foundation of Henan Province

Grant: 212300410270

Natural Science Foundation of Henan Province

Grant: 222300420069

Science and Technology Innovation Talents in Universities of Henan Province

Grant: 21HASTIT045

St. John's University

National Cancer Institute

FWCI

2.79

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://www.sciencedirect.com/science/article/pii/S2211383522001538/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2211383522001538/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211383522001538?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211383522001538?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.apsb.2022.03.023

Fields of Study

Drug Transport and Resistance MechanismsCancer therapeutics and mechanismsNanoparticle-Based Drug Delivery

Keywords

P-glycoproteinIn vivoPaclitaxelPharmacologyPyrimidineMultiple drug resistanceCancer researchChemistryCancerDoxorubicinApoptosisMedicineChemotherapyBiologyInternal medicineBiochemistryCancer therapyDrug combinationmultidrug resistance (MDR)Atp-binding CassettePreclinical StudiesP-gp InhibitorsTriazolo[1,5-a]pyrimidine

Sustainable Development Goals

SDG 0: Good health and well-being

Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor

FAIR Checklist

Authors (14)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)